Colorectal cancer is the second leading cause of death from cancer in the United States. Recent research pointed to stem cells as a significant primary driver of colorectal cancer, but exactly what happens at the cellular level inside the gut is less clear. A new study by researchers at Stevens Institute of Technology sheds, outlines a mechanism by which colorectal cancers can evolve from mature intestinal cells that revert to stem cells and suggests pathways for effective therapies.

A new study from the Institute for Health Metrics and Evaluation (IHME) at the University of Washington provides the most comprehensive and conservative analysis to date of the relationship between alcohol consumption and 20 major health outcomes.  

 

CHICAGO, MAY 31, 2026 ― Updated results from the Phase 3 BREAKWATER trial, led by researchers at The University of Texas MD Anderson Cancer Center, demonstrated a 56% reduction in the risk of disease progression or death for patients with BRAF V600E mutant metastatic colorectal cancer treated with a targeted therapy combination. 

OSUCCC – James researchers will present new findings at the 2026 American Society of Clinical Oncology (ASCO) annual meeting, including a program that helps patients get donated oral drugs faster, new insights into colon and breast cancer, and ongoing accessibility gaps across communities in clinical trials.

More than a decade after removal of an adenoma—a precancerous mass—from the colon, alterations to the gut microbiome and metabolites remain and may drive heightened risk of colorectal cancer (CRC), according to a new study led by researchers at Harvard T.H. Chan School of Public Health. The study also found that diet and physical activity were more closely tied to the abundance of these CRC-associated gut microbes in people with a history of adenoma than in adenoma-free individuals, suggesting lifestyle may play a particularly important role in shaping these microbes in this high-risk group.